Top

Drugs in R&D

Published in:

Open Access 01-06-2017 | Original Research Article

Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats

Authors: Hadeel A. Khalil, Mohammed A. W. ElKhatib, Tarek S. Belal, Ahmed F. El-Yazbi, Dalia A. Hamdy

Published in: Drugs in R&D | Issue 2/2017

Abstract

Objectives

Co-administration of posaconazole (PSZ) and vincristine (VCR) in the treatment of patients with acute lymphoblastic leukemia increases the neurotoxicity of VCR. Our aim is to study the effect of increased lipoprotein levels on the pharmacokinetics of PSZ and VCR upon co-administration in rats.

Methods

Rats were assigned to three groups, normolipidemic (NL), intermediate hyperlipidemic (IHL), and extreme hyperlipidemic (HL) groups. All rats were administered PSZ orally followed by VCR intravenously 4 h later. For the pharmacokinetic study, serial plasma samples were collected over 96 h and for tissue distribution study; plasma, lung, and liver tissues were collected over 48 h post oral dosing.

Results

Posaconazole showed higher plasma concentrations than VCR at all time points. Co-administration of VCR with PSZ reduced PSZ weight normalized oral clearance, increased PSZ area under the plasma concentration–time curve (AUC) from time zero to infinity, showed higher PSZ liver concentrations, and increased VCR volume of distribution of the central compartment. Upon increasing the lipoprotein levels, PSZ showed higher plasma availability and delayed tissue distribution, whereas VCR had shown a significant decrease in PSZ AUC_0-24h, AUC_0-tlast, and AUC_o-inf (NL = IHL > HL) and a significant increase in the volume of distribution (NL = IHL < HL). Vincristine has shown higher tissue uptake and concentrations.

Conclusion

Monitoring cholesterol and triglyceride levels in patients with acute lymphoblastic leukemia is advisable to decrease VCR neurological side effect incidences and delay the activity of both PSZ and VCR.

Bin Jardan YA, Brocks DR. The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. Biopharm Drug Dispos. 2016;37(6):345–51.CrossRef

Blaser BW, Kim HT, Alyea EP, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2012;8:575–83.CrossRef

Bourdelin M, Grenouillet F, Daguindau E, et al. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice. Med Mycol. 2014;52:728–35.CrossRefPubMed

Brocks DR, Chaudhary HR, Ben-Eltriki M, et al. Effects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitro. Can J Physiol Pharmacol. 2014;92:140–8.CrossRefPubMed

Brown MS, Goldstein, JL. Drugs used in the treatment of hyperliporoteinemias. In: Gilman AG, Goodman LS, Gilman A. The pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill Medical; 1990. pp. 874–96.

Chaudhary HR, Brocks DR. The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines. J Pharm Pharm Sci. 2013;16:65–73.CrossRefPubMed

Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47:2788–95.CrossRefPubMedPubMedCentral

Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57:218–22.CrossRefPubMedPubMedCentral

Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007;321:553–63.CrossRefPubMed

10.

Dodds Ashley ES, Varkey JB, Krishna G, et al. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother. 2009;53:2960–4.CrossRefPubMedPubMedCentral

11.

Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119:34–43.CrossRefPubMedPubMedCentral

12.

Eiden C, Palenzuela G, Hillaire-buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol/Oncol. 2009;31:292–5.CrossRef

13.

Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27:68–88.CrossRefPubMedPubMedCentral

14.

Hamdy DA, El-Geed H, El-Salem S, Zaidan M. Posaconazole–vincristine coadministration triggers seizure in a young female adult: a case report. Case Rep Hematol. 2012;2012:343742.PubMedPubMedCentral

15.

Hamdy DA, Brocks DR. Experimental hyperlipidemia causes an increase in the electrocardiographic changes associated with amiodarone. J Cardiovasc Pharmacol. 2009;53:1–8.CrossRefPubMed

16.

Hamdy DA, Brocks DR. Effect of hyperlipidemia on ketoconazole–midazolam drug–drug interaction in rat. J Pharm Sci. 2011;100:4986–92.CrossRefPubMed

17.

Hamdy DA, Brocks DR. The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat. Xenobiotica. 2011;41:137–43.CrossRefPubMed

18.

Hamdy DA, El-Salem S, El-Geed H, Zaidan M. Posaconazole, a prophylactic therapy in patients with haematological cancer: drug use evaluation study. Eur J Hosp Pharm. 2013;20:223–6.CrossRef

19.

Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976;36(10):3798–802.PubMed

20.

Khalil HA, Belal TS, El-Yazbi AF, Hamdy DA. The effect of increased lipoproteins levels on the disposition of vincristine in rat. Lipids Health Dis. 2016;15:152.CrossRefPubMedPubMedCentral

21.

Khalil HA, El-Yazbi AF, Belal TS, Hamdy DA. High performance liquid chromatographic assay for the simultaneous determination of posaconazole and vincristine in rat plasma. Int J Anal Chem. 2015;2015:743915.CrossRefPubMedPubMedCentral

22.

Khalil HA, Elnaggar MM, Belal TS, et al. The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat. Eur J Pharm Sci. 2016;91:190–5.CrossRefPubMed

23.

Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48:3543–51.CrossRefPubMedPubMedCentral

24.

Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49:379–96.CrossRefPubMed

25.

Lipp HP. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses. 2011;54(Suppl. 1):32–8.CrossRefPubMed

26.

Mahapatra M, Kumar R, Choudhry VP. Seizures as an adverse drug reaction after therapeutic dose of vincristine. Ann Hematol. 2007;86:153–4.CrossRefPubMed

27.

Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol/Oncol. 2007;29:130.CrossRef

28.

29.

Martin J, Compston N. Vincristine sulphate in the treatment of lymphoma and leukaemia. Lancet. 1963;282:1080–3.CrossRef

30.

Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.

31.

Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–7.CrossRefPubMed

32.

Nomeir AA, Kumari P, Hilbert MJ, et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother. 2000;44:727–31.CrossRefPubMedPubMedCentral

33.

Padmavathy B, Devaraj SN, Devaraj H. Effect of amiodarone, an antiarrhythmic drug, on serum and liver lipids and serum marker enzymes in rats. Indian J Biochem Biophys. 1992;29:522–4.PubMed

34.

Patel JP, Hamdy DA, El-kadi AO, Brocks DR. Effect of serum lipoproteins on stereoselective halofantrine metabolism by rat hepatocytes. Chirality. 2012;24:558–65.CrossRefPubMed

35.

Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med. 1974;80:733–7.CrossRefPubMed

36.

Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. 2014;10:483–94.CrossRefPubMed

37.

Shayeganpour A, Jun AS, Brocks DR. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos. 2005;26:249–57.CrossRefPubMed

38.

Tozuka M, Yamauchi K, Hidaka H, et al. Characterization of hypertriglyceridemia induced by l-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma. Ann Clin Lab Sci. 1997;27:351–7.PubMed

39.

van Hasselt JG, van Eijkelenburg NK, Beijnen JH, et al. Design of a drug–drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatr Blood Cancer. 2014;61:2223–9.CrossRefPubMed

40.

van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother. 2011;66:1853–6.CrossRefPubMed

41.

Wasan KM, Looije NA. Emerging pharmacological approaches to the treatment of obesity. J Pharm Pharm Sci. 2005;8:259–71.PubMed

42.

Zhou XJ, Martin M, Placidi M, et al. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet. 1990;15(4):323–32.CrossRefPubMed

Title: Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats
Authors: Hadeel A. Khalil
Mohammed A. W. ElKhatib
Tarek S. Belal
Ahmed F. El-Yazbi
Dalia A. Hamdy
Publication date: 01-06-2017
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 2/2017
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-017-0178-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Psychotropic Drug-Related Fall Incidents in Nursing Home Residents Living in the Eastern Part of The Netherlands

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy

Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration

Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU)

The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme